Core Viewpoint - The stock price of Weisheng Pharmaceutical-B (02561) has seen a significant increase, rising over 7% during trading and currently up by 3.64% to HKD 31.88, driven by positive news regarding its collaboration with Anke Bio [1] Group 1: Company Developments - Anke Bio (300009) has recently disclosed progress in its collaboration with Weisheng Pharmaceutical, specifically regarding the approval of Longpei Growth Hormone [1] - On July 14, Anke Bio announced the signing of a strategic cooperation framework agreement with Weisheng Pharmaceutical to promote the Longpei Growth Hormone in the Chinese market [1] - Weisheng Pharmaceutical's core product, Longpei Growth Hormone, had its application for market approval accepted by the National Medical Products Administration of China in March 2024, with expectations for approval in the second half of 2025 [1]

Core Insights - The company is focusing on maintaining stable growth in its traditional business while expanding into innovative drug development, particularly in the field of growth hormones and fertility treatments [6][7]. Group 1: Sales Strategy and Market Positioning - The company plans to leverage its established marketing team and extensive hospital coverage to ensure steady sales growth in growth hormones, despite a decline in newborn numbers [2]. - The collaboration with Weisheng Pharmaceutical for the long-acting growth hormone, Longpei, is positioned as a high-quality product with a unique market advantage due to its clinical validation [3]. - The company is actively promoting its long-acting follicle-stimulating hormone, Shengnuowa, through various sales channels, including private hospitals, which are not restricted by regulatory hurdles [4]. Group 2: Research and Development Progress - The company is advancing its dual-target Her2 and PD-L1*4-1BB dual antibody drugs, with plans for non-clinical research and IND application in the coming years [5]. - The establishment of the Anke Biological Innovation Research Institute aims to attract top talent and enhance R&D capabilities to overcome current research bottlenecks [6][7]. Group 3: Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 1.963 billion yuan, a year-on-year increase of 2.15%, while net profit decreased by 6.48% to 551 million yuan [8]. - The third quarter alone saw a revenue of 670 million yuan, reflecting a 7.7% year-on-year increase, with net profit rising by 6.56% to 185 million yuan [8].

Group 1: Company Overview and Leadership - Anke Bioengineering has strategic partnerships with companies like Boshengji, Afana, and Yuansong Bio, focusing on innovative drug development and commercialization [3][4][5][6] - The leadership team includes Chairman and President Song Lihua, Vice Chairman Zhou Yuanyuan, and several vice presidents overseeing various departments [2][3] Group 2: Research and Development Highlights - Boshengji's CAR-T PA3-17 has entered critical clinical trial phases, aiming for full patient enrollment by Q1 2027 and pre-NDA communication submission [3] - Yuansong Bio's lead product, recombinant L-IFN adenovirus injection, has progressed to Phase IIa clinical trials in China [5] - Afana has received clinical trial approvals for six Class I new drugs, focusing on autoimmune diseases and mRNA therapies, with significant advancements in CAR-T and HPV treatments [6][7] Group 3: Product Pipeline and Market Strategy - The company is advancing a long-acting growth hormone, expected to be approved by the end of 2025, with a focus on leveraging its commercial capabilities [4][8] - The long-acting follicle-stimulating hormone has begun market entry, with ongoing efforts to establish partnerships with private hospitals for sales [9] - The dual-target Her2 and PD-L1*4-1BB antibodies are in clinical development, with plans for IND submission in 2027 [10][11] Group 4: Financial and Market Positioning - The company aims to maintain stable growth in its traditional business while expanding into innovative drug markets [11] - Strategic focus on optimizing product structure and enhancing market competitiveness through accelerated commercialization and R&D capabilities [11] - The company is developing a comprehensive 3, 5, and 10-year strategic plan to address market challenges and enhance its positioning in the capital market [11]

证券代码：300009 证券简称：安科生物 公告编号：2025-065 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次 授予股票第三个解除限售期解除限售条件成就的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议和第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次授予股 票第三个解除限售期解除限售条件成就的议案》，同意按照《公司第三期限制性股 票激励计划（草案修订稿）》（以下简称"《第三期激励计划》"）的相关规定，对满 足解除限售条件的激励对象办理解除限售的相关事宜。现就有关事项说明如下： 一、第三期限制性股票激励计划已履行的相关审批程序 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监事会 第十九次会议，审议通过了《关于<公司第三期限制性股票激励计划（草案）>及其 摘要的议案》等相关议案。公司独 ...

关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予 股票第一个解除限售期解除限售条件部分未成就和抗肿瘤事业部 以外获授人员预留授予股票第二个解除限售期解除限售条件未成 就及回购注销部分限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 证券代码：300009 证券简称：安科生物 公告编号：2025-066 安徽安科生物工程(集团)股份有限公司 重要提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议和第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予股票第 一个解除限售期解除限售条件部分未成就和抗肿瘤事业部以外获授人员预留授予 股票第二个解除限售期解除限售条件未成就及回购注销部分限制性股票的议案》， 本次公司拟回购注销未满足解除限售条件的激励对象所持已获授但尚未解除限售 公司第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予股票第一 个解除限售期解除限售条件部分未成就和抗肿瘤事业部以外获授人员预留 授予股票第二个解除 ...

Core Points - The company announced the repurchase and cancellation of a total of 924,050 restricted stocks due to unmet vesting conditions for certain employees under its third-phase incentive plan [1][2] - The repurchase will lead to a reduction in the company's total share capital and registered capital by 924,050 shares and 924,050.00 yuan respectively, pending approval from the shareholders' meeting [2][3] Group 1: Repurchase Details - The company will repurchase 30,400 restricted stocks from the oncology division and 893,650 restricted stocks from other divisions that have not met the vesting conditions [1] - The repurchase and cancellation of these stocks will require the company to follow the procedures set by the Shenzhen Stock Exchange and the China Securities Depository and Clearing Corporation [2] Group 2: Creditor Notification - Creditors are informed that they have 45 days from the announcement date to claim their debts or request guarantees, as the repurchase will reduce the registered capital [3] - Creditors must provide valid documentation to support their claims, including contracts and identification [3][4] Group 3: Claim Submission Process - The claim submission address is provided, along with the timeline for submissions, which starts from November 26, 2024, for 45 days [4] - Contact information for the company's securities affairs department is included for any inquiries related to the claims [5]

证券日报网讯 11月25日晚间，安科生物发布公告称，公司于2025年11月24日召开第八届董事会第二十 四次会议审议通过《关于公司董事会换届选举暨第九届董事会董事候选人提名的议案》，公司第九届董 事会将由7名非独立董事、4名独立董事和1名职工代表董事组成，其中1名职工代表董事由职工代表大会 选举产生。经公司第八届董事会独立董事专门会议审核，公司董事会同意提名宋礼华先生、周源源女 士、宋礼名先生、赵辉女士、江军培先生、汪永斌先生、李坤先生为公司第九届董事会非独立董事候选 人；提名耿小平先生、陈飞虎先生、姚禄仕先生、汪律先生为公司第九届董事会独立董事候选人。 （编辑 楚丽君） ...

Group 1 - The core viewpoint of the article highlights that Anke Bio (SZ 300009) held its 24th meeting of the 8th Board of Directors on November 24, 2025, to discuss the proposal for the third extraordinary general meeting of shareholders in 2025 [1] - For the first half of 2025, Anke Bio's revenue composition is as follows: 73.51% from genetic engineering drugs, 16.77% from other businesses, and 9.72% from external patches [1] - As of the report date, Anke Bio's market capitalization stands at 16.6 billion yuan [1] Group 2 - The article also mentions that a company identified by the code 688496 is under investigation by the China Securities Regulatory Commission (CSRC) due to a significant loss exceeding 100 million yuan shortly after its IPO, with its main customer reducing purchases by using its own production [1]

证券代码：300009 证券简称：安科生物 公告编号：2025-064 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予 股票第一个解除限售期解除限售条件成就及预留授予股票第一个 解除限售期解除限售条件部分成就的公告 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监事会 第十九次会议，审议通过了《关于<公司第三期限制性股票激励计划（草案）>及其 1 本次符合解除限售条件的抗肿瘤事业部激励对象 19 名，拟解除限售的第一 类限制性股票数量合计为 662,250 股，占公司目前股本总额 1,672,521,258 股的 0.04%。其中：抗肿瘤事业部首次授予激励对象 10 名，拟解除限售的 限制性股票数量为 289,500 股；抗肿瘤事业部预留授予激励对象 19 名，拟 解除限售的限制性股票数量为 372,750 股。 本次限制性股票解除限售手续办理完成后，在上市流通前，公司将发布相 关解除限售上市流通公告，敬请投资者关注。 摘要的议案》等相关议案。公司独立董事对该事项发表了同意的独立意见，公司监 事会对本激励计划的相关事项进行核实并出 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-065 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次 授予股票第三个解除限售期解除限售条件成就的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 4、2022 年 8 月 25 日至 2022 年 9 月 5 日，公司在公司内部对本次激励计划首 次授予激励对象的姓名、部门和职务进行了公示，公示期不少于 10 天，公示期间 公司员工可向公司监事会提出意见。截至公示期满，公司监事会未收到任何组织或 个人对本次拟激励对象提出的异议。公司在巨潮资讯网披露了《安科生物：监事会 关于公司第三期限制性股票激励计划首次授予部分激励对象名单的公示情况及核 查意见的说明》。 5、2022 年 9 月 13 日，公司召开 2022 年第二次临时股东大会，审议通过了《关 于<公司第三期限制性股票激励计划（草案修订稿）>及其摘要的议案》等相关议案， 公司实施本激励计划获得股东大会批准，董事会被授权确定限制性股票授予日、在 激励对象符合条件时向激励对象授予限制 ...